Ayça Altay Benetti

Senior Researcher

National University of Singapore (NUS)
Country flagSingapore

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (18)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Chitosan, a natural polysaccharide derived from chitin, possesses biocompatibility, biodegradability, and mucoadhesive characteristics, making it an attractive material for the delivery of mRNA payloads to the nasal mucosa and promoting their uptake by target cells such as epithelial and immune cells (e.g., dendritic cells and macrophages). In this project, we aimed at developing novel lipid-based nanoformulations for mRNA delivery to counteract the pandemic caused by SARS-CoV-2 virus. The formulations achieved a mRNA encapsulation efficiency of ~80.2% with chitosan-lipid nanoparticles, as measured by the RiboGreen assay. Furthermore, the evaluation of SARS-CoV-2 Spike (S) receptor-binding domain (RBD) expression via ELISA for our vaccine formulations showed transfection levels in human embryonic kidney cells (HEK 293), lung carcinoma cells (A549), and dendritic cells (DC 2.4) equal to 9.9 ± 0.1 ng/mL (174.7 ± 1.1 fold change from untreated cells (UT)), 7.0 ± 0.2 ng/mL (128.1 ± 4.9 fold change from UT), and 0.9 ± 0.0 ng/mL (18.0 ± 0.1 fold change from UT), respectively. Our most promising vaccine formulation was also demonstrated to be amenable to lyophilization with minimal degradation of loaded mRNA, paving the way towards a more accessible and stable vaccine. Preliminary in vivo studies in mice were performed to assess the systemic and local immune responses. Nasal bronchoalveolar lavage fluid (BALF) wash showed that utilizing the optimized formulation resulted in local antibody concentrations and did not trigger any systemic antibody response. However, if further improved and developed, it could potentially contribute to the management of COVID-19 through nasopharyngeal immunization strategies.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Fok Moon Lum

Investigator

Agency for Science, Technology and Research (A*STAR)

SINGAPORE
View details

Jiong-Wei Wang

Assistant Professor

National University Health System

SINGAPORE
View details

Haruo Usuda

University of Western Australia

AUSTRALIA
View details

Yusaku Kumagai

Senior Research Fellow

Tohoku University Hospital

JAPAN
View details

Laurent Renia

Professor of Infectious Diseases

Lee Kong Chian School of Medicine, Nanyang Technological University

SINGAPORE
View details

Matthias Wacker

Professor

KU Leuven

BELGIUM
View details

Thomas Dawson

Affiliated Professor

Medical University of South Carolina

UNITED STATES
View details

Hwee Ying Lim

Research Assistant Professor

National University of Singapore (NUS)

SINGAPORE
View details

Harshvardhan Modh

Senior Research Fellow

National University of Singapore (NUS)

SINGAPORE
View details

Giorgia Pastorin

Professor

National University of Singapore (NUS)

SINGAPORE
View details

Michelle Kay Yi Seah

Senior Research Fellow

National University of Singapore (NUS)

SINGAPORE
View details

Wei Seong Toh

Associate Professor

National University of Singapore (NUS)

SINGAPORE
View details

Camillo Benetti

Lecturer

Yale-NUS College

SINGAPORE
View details